Literature DB >> 14705183

Stability of PEGylated salmon calcitonin in nasal mucosa.

Dong Hee Na1, Yu Seok Youn, Eun Ji Park, Jeong Min Lee, Ock Ryun Cho, Kang Ro Lee, Sang Deuk Lee, Sun Dong Yoo, Patrick P DeLuca, Kang Choon Lee.   

Abstract

The purpose of this study was to evaluate the stabilization of salmon calcitonin (sCT) by PEGylation in nasal mucosa. Degradation of native sCT in the homogenates of rat nasal mucosa was investigated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The initial cleavage of sCT was due to tryptic-like endopeptidase activity, and the subsequent degradation followed the sequential pattern of aminopeptidase activity. To prepare PEGylated sCT resistant to the proteolytic degradation, the lysine residues susceptible to tryptic activity were selectively PEGylated by controlling reaction pH. The PEGylated sCT showed strong resistance against enzymatic degradation in rat nasal mucosa, with 56-fold prolonged half-life compared with that of native sCT. In the MALDI-TOF MS spectrum, the PEGylated sCT did not show any degradation peak for incubation of 120 min in the homogenates of rat nasal mucosa. The improved stability may be responsible for enhancing nasal absorption of PEGylated sCT. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705183     DOI: 10.1002/jps.10537

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide).

Authors:  Dong Hee Na; Patrick P DeLuca
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

3.  PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.

Authors:  Dong Hee Na; Kang Choon Lee; Patrick P DeLuca
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

4.  Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity.

Authors:  Dong Hee Na; Jabar Faraj; Yilmaz Capan; Kai P Leung; Patrick P DeLuca
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.200

5.  In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery.

Authors:  Leonie Baginski; Oliviero L Gobbo; Frederic Tewes; Johanna J Salomon; Anne Marie Healy; Udo Bakowsky; Carsten Ehrhardt
Journal:  Pharm Res       Date:  2012-02-10       Impact factor: 4.200

6.  PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice.

Authors:  S Lee; Y S Youn; S-H Lee; Y Byun; K C Lee
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

7.  Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).

Authors:  Yun Lim Choi; Eun Ji Park; Eunje Kim; Dong Hee Na; Young-Hee Shin
Journal:  Biomol Ther (Seoul)       Date:  2014-07       Impact factor: 4.634

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.